We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Gossamer Bio

News List

Gossamer Bio Promotes Richard Aranda to CMO firstwordpharma
June 22, 2021
Gossamer Bio, Inc. (Nasdaq: GOSS) today announced that, Richard Aranda, M.D., previously Senior Vice President and Head of Clinical Development, will be promoted to Chief Medical Officer.
Gossamer Bio Appoints Sandra Milligan to its Board of Directors firstwordpharma
June 15, 2021
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics today announced the appointment of Sandra Milligan, M.D., J.D., to its Board of Directors.
Gossamer Bio secures $230m to support growth and expansion pharmaceutical-technology
July 26, 2018
US-based biotechnology company Gossamer Bio has raised $230m in a series B financing round to support its growth and pipeline expansion activities.